STOCK TITAN

Family trust reports 20.1% Celularity (CELU) stake from $10M financing

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Philip & Daniele Barach Family Trust and its co-trustees have filed an amended ownership report on Celularity Inc. The filing shows beneficial ownership of 7,558,665 shares of Celularity Class A common stock, representing 20.1% of the class based on 28,478,880 shares outstanding as of December 19, 2025.

The position is entirely made up of securities the Trust can acquire: $5,000,000 of convertible notes, convertible at $1.66 per share, and warrants covering 4,546,617 shares at a $2.00 exercise price. This stems from a December 19, 2025 financing where the Trust provided $7,000,000 in senior secured notes and $3,000,000 in convertible notes, with the option to purchase up to $2,000,000 more in convertible notes and receive additional warrants.

Positive

  • None.

Negative

  • None.

Insights

Barach family trust discloses a 20.1% economic stake in Celularity built through notes and warrants.

The filing shows the Philip & Daniele Barach Family Trust can control 7,558,665 Celularity Class A shares via convertible notes and warrants. These securities arise from a $7,000,000 senior secured note and a $3,000,000 convertible note issued on December 19, 2025, plus potential additional convertible notes.

All convertible notes carry a conversion price of $1.66 per share, and the warrants cover 4,546,617 shares at $2.00 per share, exercisable beginning June 19, 2026. The ownership equals 20.1% of 28,478,880 shares outstanding as of the financing date. The filing characterizes these as beneficially owned because the Trust can acquire them within 60 days of April 20, 2026.

Beneficially owned shares 7,558,665 shares Celularity Class A common stock reported by the Barach Reporting Persons
Ownership percentage 20.1% Portion of Celularity Class A based on 28,478,880 shares outstanding as of Dec 19, 2025
Shares outstanding 28,478,880 shares Celularity Class A common stock issued and outstanding as of Dec 19, 2025
Senior secured promissory note $7,000,000 principal Issued by Celularity to the Trust on December 19, 2025
Initial convertible note $3,000,000 principal Convertible secured promissory note issued December 19, 2025
Additional convertible notes option Up to $2,000,000 principal Two potential $1,000,000 tranches under Convertible Note Purchase Agreement
Conversion price $1.66 per share Price for all Convertible Notes into Celularity Class A shares
Warrants coverage 4,546,617 shares Total Class A shares issuable under all warrants at $2.00 exercise price
Convertible Notes financial
"All of the Convertible Notes are or will be convertible into shares of Class A Common Stock at a conversion price of $1.66 per share"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
Warrants financial
"issued to the Trust five-year warrants to purchase an aggregate of 3,707,457 shares of Class A Common Stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
senior secured promissory note financial
"the Company issued to the Trust a senior secured promissory note in the principal amount of $7,000,000"
A senior secured promissory note is a written IOU in which a borrower promises to repay a loan and gives lenders first claim on specific assets if the borrower can't pay. Being "senior" means this debt gets paid before other unsecured obligations, and "secured" means assets back the loan, reducing potential losses for lenders. For investors, that priority and collateral typically make these notes safer and often carry lower interest than unsecured debt—think of being first in line with a pledge on the borrower's car.
convertible secured promissory note financial
"a convertible secured promissory note in the aggregate principal amount of $3,000,000"
Rule 13d-3(d)(1)(i) regulatory
"The shares described in clauses (i) and (ii) are deemed beneficially owned by the Reporting Persons pursuant to Rule 13d-3(d)(1)(i)"
Convertible Note Purchase Agreement financial
"Pursuant to the Convertible Note Purchase Agreement dated as of December 19, 2025 by and between the Company and the Trust"
A convertible note purchase agreement is a contract where an investor lends money to a company through a short-term loan that can later convert into shares instead of being repaid in cash. Think of it as giving a company a loan with an agreed option to swap that loan for ownership at a future financing; it matters to investors because the conversion terms determine potential ownership, risk, timing, and how much existing shareholders may be diluted.





151190204

(CUSIP Number)
Philip & Daniele Barach Family
Philip A. Barach, Daniele Barach, 434 Surfview Drive
Pacific Palisades, CA, 90272
(818) 694-0182


Jay Coogan, Esquire
Pierson Ferdinand LLP, 1650 Market Street, 36th Floor
Philadelphia, PA, 19103
(267) 265-8598

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/20/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


PHILIP & DANIELE BARACH FAMILY TRUST
Signature:/s/ Philip A. Barach
Name/Title:Philip A. Barach, Trustee of the Trust
Date:04/22/2026
PHILIP A. BARACH
Signature:/s/ Philip A. Barach
Name/Title:Philip A. Barach
Date:04/22/2026
DANIELE BARACH
Signature:/s/ Daniele Barach
Name/Title:Daniele Barach
Date:04/22/2026

FAQ

What stake in Celularity Inc. (CELU) does the Barach Family Trust report?

The Philip & Daniele Barach Family Trust reports beneficial ownership of 7,558,665 Celularity Class A shares, equal to 20.1% of the class. This percentage is based on 28,478,880 shares outstanding as of December 19, 2025, the date of the financing transaction.

How did the Barach Family Trust acquire its Celularity (CELU) exposure?

The trust’s exposure comes from financing Celularity on December 19, 2025 via a $7,000,000 senior secured promissory note and a $3,000,000 convertible secured promissory note. These instruments, plus associated warrants and potential additional convertible notes, are convertible or exercisable into Celularity Class A shares.

What are the key conversion and exercise terms for the Celularity (CELU) securities?

All convertible notes held or potentially held by the Barach Family Trust convert into Class A shares at $1.66 per share. Warrants issued in the financing have a $2.00 per share exercise price and become exercisable on June 19, 2026, subject to adjustment provisions described in the documents.

How many Celularity (CELU) shares are tied to the Barach Family Trust’s notes?

The filing states 3,012,048 Celularity Class A shares are issuable from $5,000,000 in convertible notes, assuming the Trust elects to purchase $2,000,000 in additional convertible notes. This figure comes from applying the $1.66 per share conversion price described in the financing documents.

How many Celularity (CELU) shares are linked to warrants held by the Barach Family Trust?

The trust’s beneficial ownership includes 4,546,617 Class A shares issuable from all warrants at a $2.00 exercise price. That total includes 3,707,457 warrants issued on December 19, 2025 plus 839,160 additional warrants Celularity must issue if the Trust buys extra convertible notes.

Why are the Celularity (CELU) securities considered beneficially owned by the Barach Family Trust?

They are treated as beneficially owned under Rule 13d-3(d)(1)(i) because the Trust can acquire the shares within 60 days of April 20, 2026. This reflects its discretionary right to buy additional convertible notes, Celularity’s obligation to issue additional warrants, and the early exercisability of all warrants.